IL217404A - Doza unit, package of dozen units and inhaler for inhalation of medication combination - Google Patents
Doza unit, package of dozen units and inhaler for inhalation of medication combinationInfo
- Publication number
- IL217404A IL217404A IL217404A IL21740412A IL217404A IL 217404 A IL217404 A IL 217404A IL 217404 A IL217404 A IL 217404A IL 21740412 A IL21740412 A IL 21740412A IL 217404 A IL217404 A IL 217404A
- Authority
- IL
- Israel
- Prior art keywords
- dose
- pockets
- powder
- medication
- inhaler
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 76
- 229940079593 drug Drugs 0.000 title claims 74
- 230000007246 mechanism Effects 0.000 claims description 19
- 238000012545 processing Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims 90
- 239000004480 active ingredient Substances 0.000 claims 33
- 239000000546 pharmaceutical excipient Substances 0.000 claims 16
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 14
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 14
- 239000000556 agonist Substances 0.000 claims 14
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 14
- 229960002052 salbutamol Drugs 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 12
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 9
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 8
- 229960004436 budesonide Drugs 0.000 claims 8
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 7
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 7
- YREYLAVBNPACJM-UHFFFAOYSA-N 2-(tert-butylamino)-1-(2-chlorophenyl)ethanol Chemical compound CC(C)(C)NCC(O)C1=CC=CC=C1Cl YREYLAVBNPACJM-UHFFFAOYSA-N 0.000 claims 7
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 7
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 claims 7
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 7
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims 7
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims 7
- 229960003060 bambuterol Drugs 0.000 claims 7
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 claims 7
- 229950010713 carmoterol Drugs 0.000 claims 7
- 229960003728 ciclesonide Drugs 0.000 claims 7
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 7
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 7
- 229940112141 dry powder inhaler Drugs 0.000 claims 7
- 229960002179 ephedrine Drugs 0.000 claims 7
- 229960001022 fenoterol Drugs 0.000 claims 7
- 229960000676 flunisolide Drugs 0.000 claims 7
- 229960002714 fluticasone Drugs 0.000 claims 7
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 7
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 7
- 229960002848 formoterol Drugs 0.000 claims 7
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims 7
- 229960001268 isoetarine Drugs 0.000 claims 7
- 229960001317 isoprenaline Drugs 0.000 claims 7
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims 7
- 229960001664 mometasone Drugs 0.000 claims 7
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 7
- 229960002657 orciprenaline Drugs 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 229960001802 phenylephrine Drugs 0.000 claims 7
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 7
- 229960000395 phenylpropanolamine Drugs 0.000 claims 7
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 7
- 229960005414 pirbuterol Drugs 0.000 claims 7
- 229960005205 prednisolone Drugs 0.000 claims 7
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 7
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 7
- 229960004618 prednisone Drugs 0.000 claims 7
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 7
- 229960002720 reproterol Drugs 0.000 claims 7
- WVLAAKXASPCBGT-UHFFFAOYSA-N reproterol Chemical compound C1=2C(=O)N(C)C(=O)N(C)C=2N=CN1CCCNCC(O)C1=CC(O)=CC(O)=C1 WVLAAKXASPCBGT-UHFFFAOYSA-N 0.000 claims 7
- 229960001457 rimiterol Drugs 0.000 claims 7
- IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 claims 7
- 229960004017 salmeterol Drugs 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 229960000195 terbutaline Drugs 0.000 claims 7
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 7
- 229940110309 tiotropium Drugs 0.000 claims 7
- 229960000859 tulobuterol Drugs 0.000 claims 7
- VSWPGAIWKHPTKX-UHFFFAOYSA-N 1-methyl-10-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-5H-thieno[3,4-b][1,5]benzodiazepin-4-one Chemical compound C1CN(C)CCN1CC(=O)N1C2=CC=CC=C2NC(=O)C2=CSC(C)=C21 VSWPGAIWKHPTKX-UHFFFAOYSA-N 0.000 claims 6
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims 6
- 229960001888 ipratropium Drugs 0.000 claims 6
- NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims 6
- 229960000797 oxitropium Drugs 0.000 claims 6
- 229940044601 receptor agonist Drugs 0.000 claims 6
- 239000000018 receptor agonist Substances 0.000 claims 6
- 229950004351 telenzepine Drugs 0.000 claims 6
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 6
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 6
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims 6
- 229960001491 trospium Drugs 0.000 claims 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 5
- 229940092705 beclomethasone Drugs 0.000 claims 5
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 5
- 239000000812 cholinergic antagonist Substances 0.000 claims 5
- 238000009826 distribution Methods 0.000 claims 5
- 230000009977 dual effect Effects 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000004615 ingredient Substances 0.000 claims 5
- 239000008101 lactose Substances 0.000 claims 5
- 229960001375 lactose Drugs 0.000 claims 5
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 claims 4
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000003149 muscarinic antagonist Substances 0.000 claims 4
- -1 perenzepine Chemical compound 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000011888 foil Substances 0.000 claims 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims 2
- ASMXXROZKSBQIH-VITNCHFBSA-N aclidinium Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ASMXXROZKSBQIH-VITNCHFBSA-N 0.000 claims 2
- 229940019903 aclidinium Drugs 0.000 claims 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 150000002016 disaccharides Chemical class 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 229960000289 fluticasone propionate Drugs 0.000 claims 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000010902 jet-milling Methods 0.000 claims 2
- 229960001021 lactose monohydrate Drugs 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000002483 medication Methods 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 239000000472 muscarinic agonist Substances 0.000 claims 2
- 229960005018 salmeterol xinafoate Drugs 0.000 claims 2
- 238000004804 winding Methods 0.000 claims 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims 1
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 208000009079 Bronchial Spasm Diseases 0.000 claims 1
- 208000014181 Bronchial disease Diseases 0.000 claims 1
- 206010053582 Bronchopneumopathy Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 101150018272 FYN gene Proteins 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 239000003458 I kappa b kinase inhibitor Substances 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 102000015617 Janus Kinases Human genes 0.000 claims 1
- 108010024121 Janus Kinases Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 claims 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229940122694 Muscarinic M3 receptor antagonist Drugs 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 102000048176 Prostaglandin-D synthases Human genes 0.000 claims 1
- 108030003866 Prostaglandin-D synthases Proteins 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 102000000551 Syk Kinase Human genes 0.000 claims 1
- 108010016672 Syk Kinase Proteins 0.000 claims 1
- 206010054094 Tumour necrosis Diseases 0.000 claims 1
- 206010047924 Wheezing Diseases 0.000 claims 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 claims 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000011109 contamination Methods 0.000 claims 1
- 229960000265 cromoglicic acid Drugs 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 229960000193 formoterol fumarate Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
- 238000000265 homogenisation Methods 0.000 claims 1
- 230000035874 hyperreactivity Effects 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 229960004873 levomenthol Drugs 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229940041616 menthol Drugs 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000003681 muscarinic M3 receptor antagonist Substances 0.000 claims 1
- 230000003551 muscarinic effect Effects 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 150000002482 oligosaccharides Polymers 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 claims 1
- BHMBVRSPMRCCGG-UHFFFAOYSA-N prostaglandine D2 Natural products CCCCCC(O)C=CC1C(CC=CCCCC(O)=O)C(O)CC1=O BHMBVRSPMRCCGG-UHFFFAOYSA-N 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 229940081974 saccharin Drugs 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 235000019204 saccharin Nutrition 0.000 claims 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 1
- 229940085605 saccharin sodium Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- PJFHZKIDENOSJB-JIVDDGRNSA-N symbicort inhalation aerosol Chemical compound C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O PJFHZKIDENOSJB-JIVDDGRNSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960005294 triamcinolone Drugs 0.000 claims 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 238000001238 wet grinding Methods 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 38
- 210000003128 head Anatomy 0.000 description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 25
- 239000001301 oxygen Substances 0.000 description 25
- 229910052760 oxygen Inorganic materials 0.000 description 25
- 210000000707 wrist Anatomy 0.000 description 13
- 238000009423 ventilation Methods 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 9
- 230000000241 respiratory effect Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 238000004891 communication Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 7
- 230000003434 inspiratory effect Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 230000032258 transport Effects 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 206010038687 Respiratory distress Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000002321 radial artery Anatomy 0.000 description 4
- 239000007789 gas Substances 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000004202 respiratory function Effects 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0048—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged in a plane, e.g. on diskettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0061—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using pre-packed dosages having an insert inside
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D83/00—Containers or packages with special means for dispensing contents
- B65D83/06—Containers or packages with special means for dispensing contents for dispensing powdered or granular material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Mechanical Engineering (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Packages (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22344109P | 2009-07-07 | 2009-07-07 | |
| PCT/IB2010/052888 WO2011004287A1 (en) | 2009-07-07 | 2010-06-24 | Dose unit, pack of dose units and inhaler for inhalation of combination of drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL217404A0 IL217404A0 (en) | 2012-02-29 |
| IL217404A true IL217404A (en) | 2014-12-31 |
Family
ID=42732534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL217404A IL217404A (en) | 2009-07-07 | 2012-01-05 | Doza unit, package of dozen units and inhaler for inhalation of medication combination |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9561336B2 (enExample) |
| EP (1) | EP2451514B1 (enExample) |
| JP (1) | JP5801997B2 (enExample) |
| KR (1) | KR101419141B1 (enExample) |
| CN (1) | CN102481424B (enExample) |
| AR (1) | AR077459A1 (enExample) |
| AU (1) | AU2010269899B2 (enExample) |
| CA (1) | CA2767306C (enExample) |
| CY (1) | CY1119441T1 (enExample) |
| DK (1) | DK2451514T3 (enExample) |
| ES (1) | ES2629833T3 (enExample) |
| HU (1) | HUE034595T2 (enExample) |
| IL (1) | IL217404A (enExample) |
| MX (1) | MX348345B (enExample) |
| PL (1) | PL2451514T3 (enExample) |
| PT (1) | PT2451514T (enExample) |
| SG (1) | SG177444A1 (enExample) |
| SI (1) | SI2451514T1 (enExample) |
| TW (1) | TWI561260B (enExample) |
| WO (1) | WO2011004287A1 (enExample) |
| ZA (1) | ZA201200221B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1844808A1 (de) * | 2006-04-13 | 2007-10-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medikamenten-Ausgabevorrichtung |
| MX345867B (es) | 2011-03-21 | 2017-02-21 | Simplified Solutions Sweden Ab | Inhalador para sustancias en forma de polvo. |
| AU2013202919C1 (en) * | 2012-07-03 | 2016-02-04 | Advent Pharmaceuticals Pty Ltd | Blister Pack |
| SE537715C2 (sv) * | 2013-11-26 | 2015-10-06 | Simplified Solutions Sweden Ab | Inhalationsanordning för ämnen i pulverform |
| CN105013054B (zh) * | 2015-07-30 | 2018-11-09 | 中山市美捷时包装制品有限公司 | 一种多胶囊型干粉吸入装置 |
| CN104984448B (zh) * | 2015-07-30 | 2018-05-01 | 中山市美捷时包装制品有限公司 | 一种干粉吸入器 |
| KR101992171B1 (ko) * | 2017-06-27 | 2019-06-25 | 한국유나이티드제약 주식회사 | 건조분말 흡입기 |
| US20200324064A1 (en) * | 2019-04-10 | 2020-10-15 | Cai Gu Huang | Inhalation Device for Administering Powdered Pharmaceutical Composition |
| US12225935B2 (en) | 2019-10-04 | 2025-02-18 | Philip Morris Products S.A. | Aerosol-generating devices |
| GB2589635B (en) * | 2019-12-06 | 2021-12-01 | Merxin Ltd | Elongate form medicament carrier and medicament dispenser |
| CN114786750B (zh) * | 2019-12-18 | 2024-06-28 | 马库斯·梅兹格 | 吸入器 |
| JP2024505457A (ja) * | 2021-01-28 | 2024-02-06 | イコノヴォ アーベー | 薬剤パッケージ |
| EP4284474A4 (en) * | 2021-01-28 | 2025-01-15 | Iconovo AB | DRY POWDER INHALATOR |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9920839D0 (en) * | 1999-09-04 | 1999-11-10 | Innovata Biomed Ltd | Inhaler |
| US6971383B2 (en) * | 2001-01-24 | 2005-12-06 | University Of North Carolina At Chapel Hill | Dry powder inhaler devices, multi-dose dry powder drug packages, control systems, and associated methods |
| US7931022B2 (en) | 2001-10-19 | 2011-04-26 | Respirks, Inc. | Method and apparatus for dispensing inhalator medicament |
| MY130316A (en) | 2001-10-26 | 2007-06-29 | Pharmacia & Upjohn Co Llc | Quaternary ammonium compounds |
| GB0201677D0 (en) * | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| US7153903B1 (en) | 2002-06-19 | 2006-12-26 | The Board Of Regents Of The University Of Oklahoma | Carbon nanotube-filled composites prepared by in-situ polymerization |
| GB0217196D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
| BR0315234A (pt) | 2002-10-11 | 2005-08-23 | Pfizer | Derivados de indol como agonistas beta-2 |
| GB0315509D0 (en) * | 2003-07-02 | 2003-08-06 | Meridica Ltd | Dispensing device |
| PT1708992E (pt) | 2004-01-22 | 2007-11-16 | Pfizer | Derivados de sulfonamida para o tratamento de doenças |
| NZ548318A (en) | 2004-01-22 | 2009-03-31 | Pfizer | Sulfonamide derivatives for the treatment of diseases |
| EA200601510A1 (ru) | 2004-03-17 | 2007-04-27 | Пфайзер Инк. | Производные фенилэтаноламина в качестве бета-2-агонистов |
| AP2315A (en) | 2004-03-23 | 2011-11-04 | Pfizer | Formamide derivatives useful as adrenoceptor. |
| SE0402976L (sv) * | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
| WO2007010356A2 (en) | 2005-07-18 | 2007-01-25 | Pfizer Limited | Process for the preparation of sulfonamide derivatives |
| NZ566023A (en) | 2005-09-21 | 2010-02-26 | Pfizer Ltd | Carboxamide derivatives as muscarinic receptor antagonists |
| NZ570693A (en) | 2006-03-20 | 2011-02-25 | Pfizer Ltd | Amine derivatives |
| DE602007005387D1 (de) | 2006-09-22 | 2010-04-29 | Pfizer Ltd | Ptors |
| KR20090050104A (ko) | 2006-10-04 | 2009-05-19 | 화이자 리미티드 | 아드레날린성 효능제 및 무스카린성 길항제로서 술폰아미드 유도체 |
| US20100139655A1 (en) * | 2006-11-19 | 2010-06-10 | Aespironics Ltd | Dry-powder inhaler |
| EP1992380A1 (en) * | 2007-05-16 | 2008-11-19 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device |
| JP5328776B2 (ja) * | 2007-06-01 | 2013-10-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 小出し器具 |
| EP2200969A2 (en) | 2007-09-14 | 2010-06-30 | Pfizer Limited | Novel compounds active as muscarinic receptor antagonists |
-
2010
- 2010-06-10 JP JP2010132837A patent/JP5801997B2/ja not_active Expired - Fee Related
- 2010-06-24 CA CA2767306A patent/CA2767306C/en active Active
- 2010-06-24 DK DK10730861.1T patent/DK2451514T3/en active
- 2010-06-24 SI SI201031475A patent/SI2451514T1/sl unknown
- 2010-06-24 EP EP10730861.1A patent/EP2451514B1/en active Active
- 2010-06-24 KR KR1020127003170A patent/KR101419141B1/ko not_active Expired - Fee Related
- 2010-06-24 WO PCT/IB2010/052888 patent/WO2011004287A1/en not_active Ceased
- 2010-06-24 AU AU2010269899A patent/AU2010269899B2/en active Active
- 2010-06-24 ES ES10730861.1T patent/ES2629833T3/es active Active
- 2010-06-24 CN CN201080037227.3A patent/CN102481424B/zh active Active
- 2010-06-24 PL PL10730861T patent/PL2451514T3/pl unknown
- 2010-06-24 SG SG2011097474A patent/SG177444A1/en unknown
- 2010-06-24 US US13/380,083 patent/US9561336B2/en active Active
- 2010-06-24 MX MX2012000430A patent/MX348345B/es active IP Right Grant
- 2010-06-24 PT PT107308611T patent/PT2451514T/pt unknown
- 2010-06-24 HU HUE10730861A patent/HUE034595T2/en unknown
- 2010-07-06 TW TW099122153A patent/TWI561260B/zh not_active IP Right Cessation
- 2010-07-07 AR ARP100102448A patent/AR077459A1/es active IP Right Grant
-
2012
- 2012-01-05 IL IL217404A patent/IL217404A/en active IP Right Grant
- 2012-01-11 ZA ZA2012/00221A patent/ZA201200221B/en unknown
-
2017
- 2017-06-12 CY CY20171100618T patent/CY1119441T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2451514T (pt) | 2017-06-21 |
| KR20120042932A (ko) | 2012-05-03 |
| ZA201200221B (en) | 2013-03-27 |
| EP2451514B1 (en) | 2017-04-26 |
| MX2012000430A (es) | 2012-02-13 |
| WO2011004287A1 (en) | 2011-01-13 |
| KR101419141B1 (ko) | 2014-07-11 |
| AR077459A1 (es) | 2011-08-31 |
| CN102481424B (zh) | 2014-05-07 |
| US20120111327A1 (en) | 2012-05-10 |
| TW201106997A (en) | 2011-03-01 |
| CY1119441T1 (el) | 2018-03-07 |
| PL2451514T3 (pl) | 2017-09-29 |
| MX348345B (es) | 2017-06-06 |
| TWI561260B (en) | 2016-12-11 |
| SG177444A1 (en) | 2012-02-28 |
| DK2451514T3 (en) | 2017-07-03 |
| AU2010269899B2 (en) | 2013-06-13 |
| CN102481424A (zh) | 2012-05-30 |
| US9561336B2 (en) | 2017-02-07 |
| JP2011015958A (ja) | 2011-01-27 |
| SI2451514T1 (sl) | 2017-07-31 |
| CA2767306C (en) | 2014-05-20 |
| CA2767306A1 (en) | 2011-01-13 |
| AU2010269899A1 (en) | 2012-02-02 |
| JP5801997B2 (ja) | 2015-10-28 |
| IL217404A0 (en) | 2012-02-29 |
| HUE034595T2 (en) | 2018-02-28 |
| ES2629833T3 (es) | 2017-08-16 |
| EP2451514A1 (en) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL217404A (en) | Doza unit, package of dozen units and inhaler for inhalation of medication combination | |
| ES2666676T3 (es) | Dispositivo de administración de polvo seco | |
| EP3117858B1 (en) | Nebulizer for infants and respiratory compromised patients | |
| JP4712193B2 (ja) | 薬剤送出システム | |
| EP2950860B1 (en) | Nebulizer for infants and respiratory compromised patients | |
| WO1983003976A1 (en) | Device and method for delivery of a drug | |
| US8973574B2 (en) | System for respiratory emergencies | |
| CN104780963A (zh) | 用于具有呼吸道疾病的病人的治疗的药物供给装置 | |
| Newhouse et al. | Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates | |
| JP2006511297A (ja) | ベント型マウスピースを有する投薬システム | |
| JP2025015549A (ja) | 新生児ｃｐａｐ装置において臨床的および経済的に実現可能な吸入用量を送達するためのエアロゾルシステムおよびインターフェースの設計 | |
| GB2137886A (en) | Inhalation bag | |
| Smith | Inhalation devices for asthma and chronic obstructive pulmonary disease | |
| AU2013209385B2 (en) | Nebulizer for infants and respiratory compromised patients | |
| HK1233559A1 (en) | Nebulizer for infants and respiratory compromised patients | |
| HK40019484A (en) | Drug delivery device for the treatment of patients with respiratory diseases | |
| HK1233559B (en) | Nebulizer for infants and respiratory compromised patients | |
| Mahr et al. | Aerosols and Inhaler Therapy | |
| HK1216863B (en) | Nebulizer for infants and respiratory compromised patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |